Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | S100A4 | P26447 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8561101 | 0.81 | POLB (0.53) | MEN1KMT2AS100A4ALDH1A1POLB | |
| SCHEMBL8568380 | 0.79 | MEN1 (0.45) | MEN1KMT2AS100A4ALDH1A1POLB | |
| SCHEMBL31581131 | 0.79 | MEN1 (0.45) | MEN1KMT2AS100A4ALDH1A1POLB | |
| SCHEMBL9602589 | 0.79 | S100A4 (0.53) | MEN1KMT2AS100A4ALDH1A1POLB | |
| SCHEMBL2004290 | 0.78 | POLB (0.54) | MEN1KMT2AALDH1A1POLBMAPT | |
| SCHEMBL203184 | 0.78 | PTGES (0.44) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8566835 | 0.77 | MEN1 (0.43) | MEN1KMT2AS100A4ALDH1A1POLB | |
| SCHEMBL202663 | 0.76 | POLB (0.51) | MEN1KMT2AALDH1A1POLBMAPT | |
| SCHEMBL29381779 | 0.76 | POLB (0.51) | MEN1KMT2AALDH1A1POLBMAPT | |
| SCHEMBL21632211 | 0.76 | CYP3A4 (0.50) | MEN1KMT2AALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112624970-B | Application of 8-bit aryl substituted quinoline nitrogen oxide in plant virus resistance and sterilization | 南开大学 | 2022-10-28 | — | — | CN | disclosed |
| CN-112624970-A | Application of 8-bit aryl substituted quinoline nitrogen oxide in plant virus resistance and sterilization | 南开大学 | 2021-04-09 | — | — | CN | disclosed |
| US-8546383-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| CN-103232461-A | Synthesis method of 4-chloroquine anhydride | SUZHOU KEJIE BIOLOG PHARMACEUTICAL CO LTD | 2013-08-07 | — | — | CN | disclosed |
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-09-13 | — | — | US | disclosed |
| EP-1831226-B1 | CHIRAL TETRACYCLIC COMPOUNDS INDUCING INTERFERON BIOSYNTHESIS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8207162-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-08-25 | — | — | US | disclosed |
| US-7943609-B2 | Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides | 3M INNOVATIVE PROPRERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| CN-101823996-A | Preparation method of 2,8-bit acyl substituted quinoline | ASTA CHENGDU BIO PHARMACEUTICAL CO LTD | 2010-09-08 | — | — | CN | disclosed |
| CN-101823997-A | Preparation method of 2-bit acyl substituted quinoline | ASTA CHENGDU BIO PHARMACEUTICAL CO LTD | 2010-09-08 | — | — | CN | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| EP-1831226-A4 | CHIRAL FUSED 1,2 IMIDAZO 4,5-c RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080070907-A1 | Substituted chiral fused [1,2] imidazo [4,5-C] ring compounds and methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2008008432-A2 | SUBSTITUTED CHIRAL FUSED( 1,2) IMIDAZO (4,5-C) RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007106852-A2 | SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-1831226-A2 | CHIRAL FUSED 1,2 IMIDAZO 4,5-c RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006074003-A2 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | IFNAR1, IFNG, IL4 | MEN1 2108/4885KMT2A 3480/4885S100A4 1803/4885 |
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNAR1, IFNG, IL4 | MEN1 2062/4885KMT2A 3459/4885S100A4 1794/4885 |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNAR1, IFNG, IL4 | MEN1 2108/4885KMT2A 3480/4885S100A4 1803/4885 |
| US-20080070907-A1 | Substituted chiral fused [1,2] imidazo [4,5-C] ring compounds and methods | IFNAR1, IL2, IFNG | MEN1 2993/4885KMT2A 3186/4885S100A4 1787/4885 |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | MEN1 4112/4885KMT2A 3293/4885S100A4 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.